Human monoclonal antibody against glycoproteins of human immunodeficiency virus

Toru Sugano, Yasuhiko Masuho, Yoh ichi Matsumoto, Douglas Lake, Charles Gschwind, Eskild A. Petersen, Evan M. Hersh

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

We have established a program to make human monoclonal antibodies to the human immunodeficiency virus (HIV). Lymphocytes of lymph nodes from patients with the acquired immunodeficiency syndrome (AIDS) related complex (ARC) spontaneously produced antibodies to HIV in vitro and their antibody production was suppressed by culturing them in the presence of HIV antigens. Therefore, in vitro stimulation with HIV antigens was not done but rather, donor lymph node or spleen lymphocytes were directly fused with mouse myeloma cells. One of the hybridomas thus generated has been stably producing human monoclonal antibody (MAb) of the IgGl isotype with a kappa chain. This antibody, MAb86, bound to the surface membrane of HIV-infected cells but not to that of uninfected cells at all. MAb86 reacted in Western blot with both viral glycoproteins of 120,000 daltons (gpl20) and 41,000 daltons (gp41). While not neutralizing alone, a combination of MAb86 with another human IgGl MAb against gpl20 showed viral neutralization. Based on these data it seems likely that this approach will result in human MAbs capable of viral neutralization and antibody-dependent cytotoxicity. These may have value for the prevention and/or treatment of AIDS.

Original languageEnglish (US)
Pages (from-to)1105-1112
Number of pages8
JournalBiochemical and Biophysical Research Communications
Volume155
Issue number3
DOIs
StatePublished - Sep 30 1988
Externally publishedYes

Fingerprint

Viruses
Glycoproteins
Monoclonal Antibodies
HIV
Lymphocytes
Antibodies
Acquired Immunodeficiency Syndrome
Lymph Nodes
Viral Antibodies
Antigens
Hybridomas
Cytotoxicity
Antibody Formation
Spleen
Western Blotting
Tissue Donors
Membranes
In Vitro Techniques
Therapeutics

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Molecular Biology

Cite this

Human monoclonal antibody against glycoproteins of human immunodeficiency virus. / Sugano, Toru; Masuho, Yasuhiko; Matsumoto, Yoh ichi; Lake, Douglas; Gschwind, Charles; Petersen, Eskild A.; Hersh, Evan M.

In: Biochemical and Biophysical Research Communications, Vol. 155, No. 3, 30.09.1988, p. 1105-1112.

Research output: Contribution to journalArticle

Sugano, Toru ; Masuho, Yasuhiko ; Matsumoto, Yoh ichi ; Lake, Douglas ; Gschwind, Charles ; Petersen, Eskild A. ; Hersh, Evan M. / Human monoclonal antibody against glycoproteins of human immunodeficiency virus. In: Biochemical and Biophysical Research Communications. 1988 ; Vol. 155, No. 3. pp. 1105-1112.
@article{35ffcdfba0c3471ea9b10733cc7ff3d7,
title = "Human monoclonal antibody against glycoproteins of human immunodeficiency virus",
abstract = "We have established a program to make human monoclonal antibodies to the human immunodeficiency virus (HIV). Lymphocytes of lymph nodes from patients with the acquired immunodeficiency syndrome (AIDS) related complex (ARC) spontaneously produced antibodies to HIV in vitro and their antibody production was suppressed by culturing them in the presence of HIV antigens. Therefore, in vitro stimulation with HIV antigens was not done but rather, donor lymph node or spleen lymphocytes were directly fused with mouse myeloma cells. One of the hybridomas thus generated has been stably producing human monoclonal antibody (MAb) of the IgGl isotype with a kappa chain. This antibody, MAb86, bound to the surface membrane of HIV-infected cells but not to that of uninfected cells at all. MAb86 reacted in Western blot with both viral glycoproteins of 120,000 daltons (gpl20) and 41,000 daltons (gp41). While not neutralizing alone, a combination of MAb86 with another human IgGl MAb against gpl20 showed viral neutralization. Based on these data it seems likely that this approach will result in human MAbs capable of viral neutralization and antibody-dependent cytotoxicity. These may have value for the prevention and/or treatment of AIDS.",
author = "Toru Sugano and Yasuhiko Masuho and Matsumoto, {Yoh ichi} and Douglas Lake and Charles Gschwind and Petersen, {Eskild A.} and Hersh, {Evan M.}",
year = "1988",
month = "9",
day = "30",
doi = "10.1016/S0006-291X(88)81254-3",
language = "English (US)",
volume = "155",
pages = "1105--1112",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Human monoclonal antibody against glycoproteins of human immunodeficiency virus

AU - Sugano, Toru

AU - Masuho, Yasuhiko

AU - Matsumoto, Yoh ichi

AU - Lake, Douglas

AU - Gschwind, Charles

AU - Petersen, Eskild A.

AU - Hersh, Evan M.

PY - 1988/9/30

Y1 - 1988/9/30

N2 - We have established a program to make human monoclonal antibodies to the human immunodeficiency virus (HIV). Lymphocytes of lymph nodes from patients with the acquired immunodeficiency syndrome (AIDS) related complex (ARC) spontaneously produced antibodies to HIV in vitro and their antibody production was suppressed by culturing them in the presence of HIV antigens. Therefore, in vitro stimulation with HIV antigens was not done but rather, donor lymph node or spleen lymphocytes were directly fused with mouse myeloma cells. One of the hybridomas thus generated has been stably producing human monoclonal antibody (MAb) of the IgGl isotype with a kappa chain. This antibody, MAb86, bound to the surface membrane of HIV-infected cells but not to that of uninfected cells at all. MAb86 reacted in Western blot with both viral glycoproteins of 120,000 daltons (gpl20) and 41,000 daltons (gp41). While not neutralizing alone, a combination of MAb86 with another human IgGl MAb against gpl20 showed viral neutralization. Based on these data it seems likely that this approach will result in human MAbs capable of viral neutralization and antibody-dependent cytotoxicity. These may have value for the prevention and/or treatment of AIDS.

AB - We have established a program to make human monoclonal antibodies to the human immunodeficiency virus (HIV). Lymphocytes of lymph nodes from patients with the acquired immunodeficiency syndrome (AIDS) related complex (ARC) spontaneously produced antibodies to HIV in vitro and their antibody production was suppressed by culturing them in the presence of HIV antigens. Therefore, in vitro stimulation with HIV antigens was not done but rather, donor lymph node or spleen lymphocytes were directly fused with mouse myeloma cells. One of the hybridomas thus generated has been stably producing human monoclonal antibody (MAb) of the IgGl isotype with a kappa chain. This antibody, MAb86, bound to the surface membrane of HIV-infected cells but not to that of uninfected cells at all. MAb86 reacted in Western blot with both viral glycoproteins of 120,000 daltons (gpl20) and 41,000 daltons (gp41). While not neutralizing alone, a combination of MAb86 with another human IgGl MAb against gpl20 showed viral neutralization. Based on these data it seems likely that this approach will result in human MAbs capable of viral neutralization and antibody-dependent cytotoxicity. These may have value for the prevention and/or treatment of AIDS.

UR - http://www.scopus.com/inward/record.url?scp=0023684227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023684227&partnerID=8YFLogxK

U2 - 10.1016/S0006-291X(88)81254-3

DO - 10.1016/S0006-291X(88)81254-3

M3 - Article

VL - 155

SP - 1105

EP - 1112

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 3

ER -